Introduction:Stroke is a leading cause of adult disability and death worldwide. The neurological impairments associated with stroke prevent patients from performing basic daily activities and have enormous impact on families and caregivers. A practical and accurate tool to assist in predicting outcome after stroke at patient level, could provide significant aid for patient management and cost of healthcare delivery. Furthermore, a prediction model of this kind can be useful as a tool for clinical research, health economics, policy making, and clinical decision support.
• First prognostic tool in Stroke to follow, a priori, the Prognosis Research Strategy (PROGRESS) framework, and Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD) reporting guidelines for prognostic research.
• Pre specifies statistical analysis plan and informative levels of tool performance to increase transparency of results and of the final report.
• Restricted to only the use of predictor variables measured in previous data sets.
• Minor differences in the way variables are measured between the development and the validation data sets. 
INTRODUCTION
Stroke is among the most common cause of serious adult physical disability and the third most common cause of death worldwide (Feigin et al., 2014) . Despite the introduction of effective treatments for acute stroke, early rehabilitation and secondary prevention, the majority of stroke survivors have medical comorbidities, physical and/or cognitive impairments that require ongoing active assessment and management (Wolfe et al 2011) .
Therefore, stroke can be seen as a chronic condition, spanning not only the incident event and formal rehabilitation but the rest of the patient's life. Rehabilitation from stroke requires a sustained, co-ordinated effort from informed multidisciplinary (MDTs) as well as patients and carers, both in the clinical setting and the community (Winstein 2016 ). MDTs make numerous decisions, often in shared decision making, on the basis of an estimated probability that a specific event will occur in the future in an individual(prognosis). These Clinical prediction models(CPMs), the tests used to identify different patient risk groups, are abundant in prognostic research literature but few are implemented or used in routine clinical practice . One explanation for this is that, although models have been There is also generally a lack of confidence among clinicians in applying risk scores in practice. Many believe there is the lack of sufficient evidence to demonstrate the reproducibility and transportability of the model in a different population (Altman 2009 ). To be considered useful, a risk score should be clinically credible, accurate (well calibrated with good discriminative ability) and have generality (be externally validated) (Altman 2009 ).
We have evaluated the accuracy of existing models in predicting stroke outcomes by systematic review of literature and meta-analysis. The report concluded no clinical prediction models were sufficiently accurate to become part of routine care (Fahey et al 2016) . Models were poorly reported, this further undermines clinicians confidence in the models ability to support patients. One of the recommendations from that research was to build on previous work in developing clinical prediction models suitable for routine care.
This aim of this study is the develop and validate (temporally and geographically) clinical prediction models for mortality, functional outcome and cognitive impairment after stroke.
METHODS
Our study design is informed by the PROGRESS framework and specific recommendations for statistical approaches to prognostic research. We will report the study in accordance with the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement for prediction studies (Collins et al 2015) .
The PROGRESS framework outlines four types of prognostic research: (1) 
Source of data
The study is a prospective longitudinal cohort study. 
Participants
Patients admitted to hospitals serving the study area (two teaching hospitals within and three hospitals outside the study area) are identified by regular reviews of acute wards admitting stroke patients, , national data on patients admitted to any hospital in England and Wales with a diagnosis of stroke are screened for additional patients. 
Outcome
The start point for these models is time of stroke and outcomes of interest are Mortality not composite. This is a secondary data analysis so data collection is carried out by a third party, uninvolved in this research. Outcomes are assessed at baseline, at three months and annually thereafter.
Predictors
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Missing data
Modelling method
We will develop three clinical prediction models; one for mortality, one for functional outcome and one for cognitive impairment. The start point is time of stroke and end point 5 years post stroke.
For predictors selection during multivariate modelling a variable selection and shrinkage procedure will be used to decide which of the identified candidate predictor variables should be included in the final prediction model. Continuous variables will be kept as continuous (rather than say dichotomising), to avoid a loss of power. Non-linear trends will also be considered using fractional polynomials and the multivariable fractional polynomial procedure. Clinically meaningful interactions will be included in the model.
We will assess internal validity with a bootstrapping procedure for a realistic estimate of the performance of both prediction models in similar future patients (Steyerberg 2009; Harrell et al 1996) . Our approach is as follows:
1. Develop the prediction model using the entire original sample and determine the apparent performance.
2. Generate a bootstrap sample, by sampling n individuals with replacement from the original sample.
3. Develop a model using the bootstrap sample (applying all the same modelling and predictor selection methods, as in step 1):
a. Determine the performance (described below) of this model on the bootstrap sample (bootstrap performance). 5. Repeat steps 2 through 4 at least 500 times.
6. Average the estimates of optimism in step 5, and subtract the value from the performance obtained in step 1 to obtain an optimism-corrected estimate of performance.
The bootstrap validation approach uses all of the data to develop the prediction model and provides a mechanism to account for model overfitting or uncertainty in the entire model development process, thereby quantifying any optimism in the final prediction model. Also, it provides for estimating a shrinkage factor that can be used to adjust the regression coefficients and apparent performance for optimism, such that better performance will be obtained in subsequent model validation studies and applications (Collins et al 2015) . Once a final model is identified, methods will be applied to simplify and adapt the presentation of the model to a scoring system to facilitate its application in practice.
Model performance
Model performance will be assessed in both the derivation and validation datasets. For model development studies, we are primarily interested in discrimination, because the model will be well calibrated (on average) by definition and even perfect when the smoothed method is used. In validation studies, assessment of both discrimination and calibration is fundamental (Steyerberg et al 2010, Vickers and Cronin 2010).
Calibration of the derived models will be measured using calibration plot and Hosmer- 
Model Evaluation
Developed models will be validated temporally using the SLSR. To provide evidence evidence that the model performs well for other (external) patients we will externally validate in data collected by the Dijon Stroke Register(DSR). This geographical validation will enable us to assess the prognostic performance and the generalisability of the model. The methods of the DSR have been described previously in detail (Giroud 1997 We will update the model if it shows poor performance to adjust to the new situation by recalibration or revision methods depending on discrimination performance (c-statistics <0.80). If model is updated updating approaches recommended by Steyerberg (model recalibration, model revision, model extension) will be adopted as appropriate ). of clinical prediction models for stroke over the long term. To our knowledge, this tool will be the first of its kind in stroke to follow, a priori, the PROGRESS framework and TRIPOD reporting guidelines for prognostic research. Importantly for secondary prevention, the tool will be developed specifically to predict the progression of disease and identify those at high risk of an adverse outcome. . Results coming from this study will be interpreted for both clinical and research purposes. 
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• The proposed study predicts outcomes longitudinally, which may be more reflective of clinical needs than predictions made at pre-defined time points.
• The proposed study is restricted by the use of predictor variables measured in previous data sets and the limitations of these measures. The external validation is not independent. of an estimated probability that a specific event will occur in the future. These predictions are used for planning lifestyle or therapeutic decisions on the basis of the risk of developing a particular outcome or state of health. [4] [5] [6] More recently such estimates are used to riskstratify participants in therapeutic intervention trials and case mix classifications. [7, 8] Information from a single predictor is often insufficient to provide reliable estimates of prognostic probabilities or risks, particularly in complex patients, for example those with comorbidities. [9, 10] Therefore probability estimates are commonly based on combining information from multiple predictors to form a multivariable clinical prediction model (CPM). [11, 12] CPMs are abundant in prognostic research literature but few are implemented or used in routine clinical practice. [13] One explanation for this is that, although many models have been developed, [14, 15] they have limited utility for clinical applications, particularly in a long term care setting. Progression or regression of disease is highly variable both over time and There is generally a lack of confidence among clinicians in applying risk scores in practice.
Many believe there is the lack of sufficient evidence to demonstrate the reproducibility and transportability of the model in a different population (Altman 2009 ). To be considered useful, a risk score should be clinically credible, accurate (well calibrated with good discriminative ability) and have generality (be externally validated). [17] We have evaluated the accuracy of existing models in predicting stroke outcomes by systematic review of literature and meta-analysis. The systematic review and meta analysis concluded that existing models have much potential and advised to build on previous work, opposed to designing new models, in developing clinical prediction models suitable for the long term care setting. [15] Models predicting outcomes longitudinally, opposed to predefined time points, may best support patient management and so we will build on work by colleagues in this area. [18, 19] 
OBJECTIVES
Primary objectives
To develop and to internally validate prediction models in patients with ischemic stroke for functional outcome, survival and cognitive impairment at five years. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 To externally validate and to update these models through an external dataset of ischemic stroke patients.
Secondary objectives
To Assess deviations of predicted recovery curves.
To investigate why stroke patients regain different recovery that plateaued at different levels.
To derive and validate scoring system for classifying risks (case-mix classification) from these patient-centred predictive models
METHODS
This cohort study is informed by the PROGRESS framework and recommendations by authors in the field. We will report the study protocol using the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement for prediction studies. [20] 
Source of data
The study is a prospective longitudinal cohort study. The data source is the South London Stroke Register(SLSR) an ongoing, prospective population-based stroke register set up in January 1995 recording all first-ever strokes in patients of all ages for an inner area of South
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Predictors
Candidate predictors to be considered in the prediction models will be based on predictor variables as identified in previous systematic reviews in this field, [15, 22] ease and reliability of measurement in clinical setting and theoretical association with the progression of outcomes. The number of variables required to ensure adequate power based on our target sample size (see below), to avoid overfitting, and to encourage parsimony and applicability of the model in clinical practice will also be considered. Number, type, definition, method for measurement and handling of candidate predictors in the modelling are listed in the data supplement. All predictors are measured at patient presentation. Data collection is carried out by a third party, not involved in this research.
Sample size
Cumulative survival up to 10 years after stroke is estimated at 63.7%, 42.8% and 24.0%, surviving up to 1, 5 and 10 years respectively. [2] Disability is estimated on average at 11% (10 year average and standardised to European population in the SLSR Jinks will be used for survival analysis. [25] Simulation will be used to determine appropriate sample size for models prediction functional outcome and cognitive impairment.
Missing data
Missing data is inevitable in studies with long follow up and may lead to bias and imprecision. Multiple imputation will be used to impute missing values, under a missing at random assumption, so as to reduce bias and avoid excluding participants from the analysis. [26] [27] [28] [29] [30] Imputations typically break down when missing data is excessive, therefore data with more than 80% missing data will be excluded.
Statistical analysis methods
We will develop three clinical prediction models for the outcomes : (i) mortality , (ii) functional outcome and (iii) cognitive impairment up to five years after stroke. The start point is time of stroke and end point 5 years post stroke.
For predictor selection during multivariate modelling a variable selection and shrinkage procedure will be used to decide which of the identified candidate predictor variables should be included in the final prediction model. Continuous variables will be kept as continuous (rather than say dichotomising), to avoid a loss of power. Non-linear trends will be considered using fractional polynomials and the multivariable fractional polynomial procedure. Clinically meaningful interactions (e.g time) will be included in the model. We will assess internal validity with a bootstrapping procedure for a realistic estimate of the performance of prediction models in similar future patients. [5, 12] The bootstrap validation approach uses all of the data to develop the prediction model and provides a mechanism to account for model overfitting or uncertainty in the entire model development process, thereby quantifying any optimism in the final prediction model. Also, it provides for estimating a shrinkage factor that can be used to adjust the regression coefficients and apparent performance for optimism, such that better performance will be obtained in subsequent model validation studies and applications. [31] External validity will be assessed using data form the Dijon Stroke Register (DSR). Patients will be classified using the estimates of the previously developed models and performance assessed. Subgroup analyses will be carried out to assess deviations from predicted recovery trajectories and investigate why stroke patients regain different recovery that plateaued at different levels.
Risk groups
Although risk groups (e.g. "high risk", "moderate risk", "low risk") may make models more accessible, no risk groups will be created. There is no clear consensus on how to create risk groups or how many groups to use. [31] There are concerns that use of risk groups may not be in the best interest of patients and may become standard although lacking any rational. [31] Also, the simplification of predicted probabilities assumes risk is the same for all individuals within that category. Data from the Dijon Stroke Register (DSR) will be used for external validation; it's methods have been described previously in detail [32] [33] [34] and both datasets are contrasted here. The DSR and SLSR are population-based registers, multiple overlapping sources of notification are used and stroke is defined according to World Health organisation criteria for both.
Development vs. Validation
Specially trained field workers collect all data. This includes sociodemographic factors, disease characteristics patient history and cardiovascular risk factors in both registers. DSR participants are followed up at time of stroke and yearly thereafter; these questionnaires are administered in out-patient clinics or conducted telephonically by clinical nurses. Follow up procedures in SLSR are similar but participants are followed up at three months also. In both registers, survival is measured using national data, Cognitive status is measured using either the Abbreviated Mental Test (AMT) or the Mini Mental State Exam (MMSE) and disability is measured using Barthel Index (BI).
REPORTING OF RESULTS
Participants
The flow of participants through the study, including the number of participants with and without the outcome and a summary of the follow-up time will be described. The characteristics of the participants including the number of participants with missing data for predictors and outcome for both development and validation cohorts will be provided.
Model development
The number of participants and outcome events in each analysis will be presented as well as the unadjusted association between each candidate predictor and outcome. 
Model specification
The full prediction model for each outcome will be presented including all regression coefficients, and model intercept and baseline survival. Once a final model is identified, methods will be applied to simplify and adapt the presentation of the model to a scoring system to facilitate its application in practice at a later date. An explanation of how to use the model and scoring system will also be presented.
Model performance
Model performance assessment has been designed using the framework described by miscalibration, hence calibration plots will also be presented. Calibration plots will also be evaluated in relation to key predictors/subgroups. Discrimination of the derived models will be measured using the concordance statistic and confidence intervals (c-statistic). The cindex is identical to the area under the receiver-operating characteristic curve (AUROC) for models with binary endpoints, and can be generalized for time-to-event (survival) models accounting for censoring. A benchmark level of discrimination was determined in our metaanalysis for mortality and functional outcome. On the basis of the reference standard values 
Model updating
We will update the model if it shows poor performance in external data(DSR) by recalibration or revision methods depending on discrimination performance (c-statistics <0.80). If model is updated updating approaches recommended by Steyerberg (model recalibration, model revision, model extension) will be adopted as appropriate.
[13]
CONCLUSION
We have described the methods and statistical analysis plan to develop and to validate a family of clinical prediction models for stroke over the long term. To our knowledge, this tool will be the first of its kind in stroke to follow, a priori, the PROGRESS framework and TRIPOD reporting guidelines for prognostic research. Importantly for secondary prevention, the tool will be developed specifically to predict the progression of disease and to identify those at high risk of an adverse outcome. Results coming from this study will be interpreted for both clinical and research purposes. 
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